Clinical TrialID 2587

A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)

NCT02288091

Amyotrophic Lateral Sclerosis

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab

Trial: 1Ingredient: 1Links: 1

Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id: 2587
Evidence Id: 2587
Core Evidence Id: 2587
Source Clinical Trial Id: 2566
Herb2 Clinical Trial Id: HBCT002566
Nct Id: NCT02288091
Title: A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)
Status: Completed
Phase: Phase 1
Study Result: Yes
Study Condition: Amyotrophic Lateral Sclerosis
Study Type: Interventional
Study Design: Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Intervention: DRUG: Inosine
Intervention Allocation
Intervention Model: Single_Group
Intervention Mask
Intervention Purpose: Treatment
Gender: All
Age: Adult, Older_Adult
Enrollment: 32
Outcome Measure: Number of Participants Experiencing Adverse Events, Safety will be assessed by the occurrence of adverse events., 12 weeks|Tolerability to Complete the Entire 12 Week Study on Study Drug., Tolerability will be defined as the ability of subjects to complete the entire 12-week study on study drug., 12 weeks
Sponsor Collaborator: Massachusetts General Hospital|The Salah Foundation|MGH cure ALS Fund
Funded By: OTHER
Location: Massachusetts General Hospital, Boston, Massachusetts, 02114, United States
Other Id: 701
Start Date: 2015-01
Primary Completion Date: 2016-03
Completion Date: 2016-03
First Posted: 2014-11-11
Results First Posted: 2017-10-02
Last Update Posted: 2017-11-06
Study Document
Study Url: https://clinicaltrials.gov/study/NCT02288091
Title Cn
Title En: A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)
Bilingual Status: semi_complete